Li‐Tain Yeh

1.5k total citations
50 papers, 1.2k citations indexed

About

Li‐Tain Yeh is a scholar working on Infectious Diseases, Hepatology and Oncology. According to data from OpenAlex, Li‐Tain Yeh has authored 50 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Infectious Diseases, 20 papers in Hepatology and 14 papers in Oncology. Recurrent topics in Li‐Tain Yeh's work include Hepatitis C virus research (20 papers), HIV/AIDS drug development and treatment (19 papers) and Gout, Hyperuricemia, Uric Acid (11 papers). Li‐Tain Yeh is often cited by papers focused on Hepatitis C virus research (20 papers), HIV/AIDS drug development and treatment (19 papers) and Gout, Hyperuricemia, Uric Acid (11 papers). Li‐Tain Yeh collaborates with scholars based in United States, United Kingdom and Italy. Li‐Tain Yeh's co-authors include Chin‐Chung Lin, Barry Quart, Zancong Shen, Jeffrey N. Miner, Christine Xu, Kimberly J. Manhard, Zhi Hong, Cory Iverson, Robert Hamatake and Jean‐Luc Girardet and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Li‐Tain Yeh

49 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Li‐Tain Yeh United States 22 419 327 293 277 245 50 1.2k
Yu Toyoda Japan 22 457 1.1× 91 0.3× 71 0.2× 170 0.6× 386 1.6× 61 1.3k
Lorea Mendoza Spain 17 536 1.3× 45 0.1× 65 0.2× 88 0.3× 91 0.4× 21 1.1k
Zhiwei Chen China 18 277 0.7× 126 0.4× 253 0.9× 375 1.4× 21 0.1× 80 1.1k
Grushenka H.I. Wolfgang United States 18 219 0.5× 134 0.4× 565 1.9× 759 2.7× 16 0.1× 37 1.4k
Salah‐Dine Chibout Switzerland 18 352 0.8× 95 0.3× 36 0.1× 122 0.4× 152 0.6× 40 1.1k
R. Wayne Rundles United States 20 545 1.3× 110 0.3× 41 0.1× 245 0.9× 329 1.3× 37 1.6k
Stuart Oliver United Kingdom 17 290 0.7× 232 0.7× 43 0.1× 216 0.8× 15 0.1× 29 1.1k
Kazuko Kobayashi Japan 27 481 1.1× 94 0.3× 19 0.1× 195 0.7× 57 0.2× 89 2.0k
Yannick Laperche France 26 680 1.6× 57 0.2× 295 1.0× 330 1.2× 19 0.1× 51 1.6k
Robert M. Rydzewski United States 14 628 1.5× 137 0.4× 210 0.7× 725 2.6× 9 0.0× 22 1.5k

Countries citing papers authored by Li‐Tain Yeh

Since Specialization
Citations

This map shows the geographic impact of Li‐Tain Yeh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Li‐Tain Yeh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Li‐Tain Yeh more than expected).

Fields of papers citing papers by Li‐Tain Yeh

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Li‐Tain Yeh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Li‐Tain Yeh. The network helps show where Li‐Tain Yeh may publish in the future.

Co-authorship network of co-authors of Li‐Tain Yeh

This figure shows the co-authorship network connecting the top 25 collaborators of Li‐Tain Yeh. A scholar is included among the top collaborators of Li‐Tain Yeh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Li‐Tain Yeh. Li‐Tain Yeh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Wei, James Cheng‐Chung, Roy Fleischmann, Shannon R. Morris, et al.. (2023). OP0295 A 12-WEEK, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, PHASE 2B STUDY OF SAFETY, TOLERABILITY AND EFFICACY OF AR882 IN GOUT PATIENTS. Annals of the Rheumatic Diseases. 82. 192–192. 5 indexed citations
3.
4.
Miner, Jeffrey N., Philip K. Tan, David Hyndman, et al.. (2016). Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney. Arthritis Research & Therapy. 18(1). 214–214. 107 indexed citations
5.
Adjei, Alex A., Donald Richards, Anthony B. El-Khoueiry, et al.. (2015). A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer. Clinical Cancer Research. 22(10). 2368–2376. 16 indexed citations
6.
Fleischmann, R., Bradley M. Kerr, Li‐Tain Yeh, et al.. (2014). Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia. Lara D. Veeken. 53(12). 2167–2174. 81 indexed citations
7.
Weekes, Colin D., Daniel D. Von Hoff, Alex A. Adjei, et al.. (2013). Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer. Clinical Cancer Research. 19(5). 1232–1243. 46 indexed citations
8.
Nagasawa, Johnny, Jenny Z. Song, Huanming Chen, et al.. (2010). 6-Benzylamino 4-oxo-1,4-dihydro-1,8-naphthyridines and 4-oxo-1,4-dihydroquinolines as HIV integrase inhibitors. Bioorganic & Medicinal Chemistry Letters. 21(2). 760–763. 22 indexed citations
9.
Iverson, Cory, Gary Larson, Chon Lai, et al.. (2009). RDEA119/BAY 869766: A Potent, Selective, Allosteric Inhibitor of MEK1/2 for the Treatment of Cancer. Cancer Research. 69(17). 6839–6847. 153 indexed citations
10.
Hamatake, Robert, Li‐Tain Yeh, Hong Kim, et al.. (2007). RDEA119: A potent and highly selective MEK inhibitor for the treatment of cancer. Molecular Cancer Therapeutics. 6. 3 indexed citations
11.
Benetton, Salete, et al.. (2007). P450 Phenotyping of the Metabolism of Selegiline to Desmethylselegiline and Methamphetamine. Drug Metabolism and Pharmacokinetics. 22(2). 78–87. 24 indexed citations
12.
Gunić, Esmir, Jean‐Luc Girardet, Kanda S. Ramasamy, et al.. (2007). Cyclic monophosphate prodrugs of base-modified 2′-C-methyl ribonucleosides as potent inhibitors of hepatitis C virus RNA replication. Bioorganic & Medicinal Chemistry Letters. 17(9). 2452–2455. 32 indexed citations
13.
Yeh, Li‐Tain, et al.. (2006). LC–MS/MS method for simultaneous determination of viramidine and ribavirin levels in monkey red blood cells. Journal of Pharmaceutical and Biomedical Analysis. 43(3). 1057–1064. 21 indexed citations
14.
Liu, Yifei, et al.. (2006). Sensitive and specific LC–MS/MS method for the simultaneous measurements of viramidine and ribavirin in human plasma. Journal of Chromatography B. 832(1). 17–23. 30 indexed citations
15.
Wu, Jim Zhen, Li‐Tain Yeh, Chin‐Chung Lin, & Zhi Hong. (2006). Conversion of Viramidine to Ribavirinin Vivoby Adenosine Deaminase and its Inhibition by 2′-Deoxycoformycin. Antiviral chemistry & chemotherapy. 17(1). 33–39. 5 indexed citations
16.
Lin, Chin‐Chung, et al.. (2005). Pharmacokinetics of Pradefovir and PMEA in Healthy Volunteers After Oral Dosing of Pradefovir. The Journal of Clinical Pharmacology. 45(11). 1250–1258. 15 indexed citations
17.
Lin, Chin‐Chung, et al.. (2004). Pharmacokinetics and Safety of Viramidine, a Prodrug of Ribavirin, in Healthy Volunteers. The Journal of Clinical Pharmacology. 44(3). 265–275. 44 indexed citations
18.
Xu, Christine, et al.. (2004). Viramidine Demonstrates Better Safety Than Ribavirin in Monkeys But Not Rats. Drug and Chemical Toxicology. 27(3). 191–211. 7 indexed citations
19.
Yeh, Li‐Tain, Mai Nguyen, & Chin‐Chung Lin. (2003). A Sensitive and Specific Method for the Determination of Total Ribavirin in Human Red Blood Cells by Liquid Chromatography-Tandem Mass Spectrometry. Journal of Chromatographic Science. 41(5). 255–260. 29 indexed citations
20.
Lin, Chin‐Chung, Li‐Tain Yeh, & Johnson Y.N. Lau. (2002). Specific, sensitive and accurate liquid chromatographic–tandem mass spectrometric method for the measurement of ribavirin in rat and monkey plasma. Journal of Chromatography B. 779(2). 241–248. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yu Toyoda Breakdown of academic impact, for papers by Lorea Mendoza Breakdown of academic impact, for papers by Zhiwei Chen Breakdown of academic impact, for papers by Grushenka H.I. Wolfgang Breakdown of academic impact, for papers by Salah‐Dine Chibout Breakdown of academic impact, for papers by R. Wayne Rundles Breakdown of academic impact, for papers by Stuart Oliver Breakdown of academic impact, for papers by Kazuko Kobayashi Breakdown of academic impact, for papers by Yannick Laperche Breakdown of academic impact, for papers by Robert M. Rydzewski
Rankless by CCL
2026